Detalhe da pesquisa
1.
Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer.
J Transl Med;
21(1): 637, 2023 09 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37726776
2.
Computational markers for personalized prediction of outcomes in non-small cell lung cancer patients with brain metastases.
Clin Exp Metastasis;
41(1): 55-68, 2024 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38117432
3.
Killing a fly with a sledgehammer: Atezolizumab exposure in real-world lung cancer patients.
CPT Pharmacometrics Syst Pharmacol;
12(11): 1795-1803, 2023 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38011601
4.
Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome.
Lung Cancer;
169: 31-39, 2022 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35609409
5.
The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung Cancer.
Pharmgenomics Pers Med;
14: 987-996, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34429632
6.
[Predictable toxicities with futures immunotherapies or combinations]. / Toxicités à prévoir avec les futures immunothérapies ou associations.
Bull Cancer;
107(10): 1069-1078, 2020 Oct.
Artigo
em Francês
| MEDLINE
| ID: mdl-32977938
7.
Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?
Transl Lung Cancer Res;
8(Suppl 4): S383-S386, 2019 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32038920